{"id":62857,"date":"2026-03-28T01:03:02","date_gmt":"2026-03-28T00:03:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/"},"modified":"2026-03-28T01:03:02","modified_gmt":"2026-03-28T00:03:02","slug":"lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/","title":{"rendered":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report"},"content":{"rendered":"<div>\n<p>DALLAS&#8211;(BUSINESS WIRE)&#8211;Lantern Pharma Inc. (NASDAQ: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI\u2011driven, clinical\u2011stage oncology company leveraging its proprietary RADR<sup>\u00ae<\/sup> platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third\u2011party website.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/5\/Lanternlogo_square.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/5\/Lanternlogo_square.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/21\/Lanternlogo_square.jpg\"><\/a><\/p>\n<p>\nThe third\u2011party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors.<\/p>\n<p>\nMr. Sharma continues to serve as President, Chief Executive Officer, and a Director of Lantern, and remains fully engaged in leading the Company\u2019s strategy, operations, and portfolio of AI\u2011driven oncology programs. He has no intention to step down from his roles with Lantern and he has not been requested to do so. As previously announced on March 23, 2026, Mr. Sharma will lead Lantern\u2019s upcoming webcast to discuss fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time.<\/p>\n<p>\nNeither Lantern nor its Board of Directors has approved or planned any CEO change. Any report suggesting otherwise is without merit.<\/p>\n<p>\nDonald Jeff Keyser, Chairman of Lantern\u2019s Board of Directors, stated: \u201cThe Board has full confidence in Panna Sharma\u2019s leadership. Under his direction, Lantern continues to advance a robust clinical pipeline, including the recently cleared IND for Starlight Therapeutics\u2019 planned Phase 1 pediatric CNS cancer trial of STAR-001 and the continued expansion of the Company\u2019s AI\u2011driven drug development capabilities. We are disturbed by what appears to be a deliberate third\u2011party attempt to mislead investors and the market, and will pursue immediate corrective actions.\u201d<\/p>\n<p>\nLantern cautions investors and other stakeholders to be vigilant against potential third\u2011party attempts to manipulate Lantern\u2019s stock price through the dissemination of false or misleading information. Investors are encouraged to rely solely on Lantern\u2019s official communications, including filings with the U.S. Securities and Exchange Commission and press releases available on the Company\u2019s investor relations website.<\/p>\n<p>\nThe Company is actively investigating the origin and dissemination of today\u2019s fabricated third\u2011party article, including any coordinated trading activity surrounding its publication. Lantern intends to pursue all available legal remedies and is considering referring this matter to the appropriate regulatory authorities.<\/p>\n<p>\n<b>Details for Q4 and Fiscal Year 2025 Webcast<\/b><\/p>\n<p>\nAs previously disclosed, Lantern will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on Monday, March 30, 2026, at 4:30 p.m. Eastern Time. Mr. Sharma will lead the discussion and management intends to review results for the period ended December 31, 2025, and provide updates on key clinical programs and the continued evolution of the RADR<sup>\u00ae<\/sup> AI platform.<\/p>\n<p>\nAdditional details, including webcast access information and a replay of the webcast, will be available on the Events &amp; Presentations section of Lantern\u2019s investor relations website.<\/p>\n<p>\n<b>About Lantern Pharma<\/b><\/p>\n<p>\nLantern Pharma Inc. (NASDAQ: LTRN) is a clinical\u2011stage biopharmaceutical company using its proprietary RADR<sup>\u00ae<\/sup> artificial intelligence and machine learning platform to transform the cost, pace, and outcomes of oncology drug development. Lantern\u2019s RADR<sup>\u00ae<\/sup> platform analyzes extensive genomic and drug response data to identify biomarkers that predict patient response, enabling more efficient and targeted clinical trials. For more information, visit <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lanternpharma.com&amp;esheet=54469127&amp;newsitemid=20260327821422&amp;lan=en-US&amp;anchor=www.lanternpharma.com&amp;index=1&amp;md5=145b3270a87eed762916c2cc16f321d6\" rel=\"nofollow\" shape=\"rect\">www.lanternpharma.com<\/a><\/i>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Relations Contact:<\/b><br \/>Lantern Pharma Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x69;&#x72;&#x40;&#x6c;&#x61;&#x6e;&#x74;&#101;&#114;&#110;&#112;&#104;&#97;&#114;&#109;&#97;&#46;&#99;om\" rel=\"nofollow\" shape=\"rect\">&#105;&#x72;&#64;&#108;&#x61;n&#116;&#x65;r&#110;&#x70;h&#97;&#x72;&#109;&#x61;&#x2e;&#99;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS&#8211;(BUSINESS WIRE)&#8211;Lantern Pharma Inc. (NASDAQ: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI\u2011driven, clinical\u2011stage oncology company leveraging its proprietary RADR\u00ae platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third\u2011party website. The third\u2011party article incorrectly claimed that Panna &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62857","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DALLAS&#8211;(BUSINESS WIRE)&#8211;Lantern Pharma Inc. (NASDAQ: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI\u2011driven, clinical\u2011stage oncology company leveraging its proprietary RADR\u00ae platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third\u2011party website. The third\u2011party article incorrectly claimed that Panna ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-28T00:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report\",\"datePublished\":\"2026-03-28T00:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260327821422\\\/en\\\/1827644\\\/22\\\/Lanternlogo_square.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/\",\"name\":\"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260327821422\\\/en\\\/1827644\\\/22\\\/Lanternlogo_square.jpg\",\"datePublished\":\"2026-03-28T00:03:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260327821422\\\/en\\\/1827644\\\/22\\\/Lanternlogo_square.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260327821422\\\/en\\\/1827644\\\/22\\\/Lanternlogo_square.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/","og_locale":"en_US","og_type":"article","og_title":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend","og_description":"DALLAS&#8211;(BUSINESS WIRE)&#8211;Lantern Pharma Inc. (NASDAQ: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI\u2011driven, clinical\u2011stage oncology company leveraging its proprietary RADR\u00ae platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third\u2011party website. The third\u2011party article incorrectly claimed that Panna ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-28T00:03:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report","datePublished":"2026-03-28T00:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/"},"wordCount":586,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/","url":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/","name":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg","datePublished":"2026-03-28T00:03:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260327821422\/en\/1827644\/22\/Lanternlogo_square.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62857"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62857\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}